Suspended in culture — Human pluripotent cells for scalable technologies  by O'Brien, Carmel & Laslett, Andrew L.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
www.e l sev i e r . com/ loca te / sc r
Stem Cell Research (2012) 9, 167–170REGULAR ARTICLE
Suspended in culture — Human pluripotent cells for
scalable technologies
Carmel O'Brien⁎, Andrew L. LaslettCSIRO Materials Science and Engineering, Stem Cells, Clayton, Victoria, Australia
Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, AustraliaAbstract Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), collectively
termed human pluripotent stem cells (hPSCs), are typically derived and maintained in adherent and semi-defined culture
conditions. Recently a number of groups, including Chen et al., 2012, have demonstrated that hESCs can now be
expanded efficiently and maintain pluripotency over long-term passaging as aggregates in a serum-free defined
suspension culture system, permitting the preparation of scalable cGMP derived hPSC cultures for cell banking, high
throughput research programs and clinical applications. In this short commentary we describe the utility and potential future
uses of suspension culture systems for hPSCs.
© 2012 Published by Elsevier B.V.Introduction
Human pluripotent stem cells are notable for their remarkable
capacity to self-renew indefinitely in vitro and to give rise to
tissues comprising the three embryonic germ layers in the
formation of teratomas in vivo. hPSCs are an important cell
source for the study of human disease processes, screening for
candidate therapeutic agents and potentially for regenerative
cell-based therapies and tissue engineering applications. The
realisation of this potential still requires improved in vitro
differentiation assays for the efficient generation of target
cell types as well as effective strategies for purification of these
from non-target somatic cells and residual hPSCs. Development
of defined culture systems that enable scalable long term ex-
pansion of hPSCs, is an important first step towards the repro-
ducible seeding of robust differentiation technologies.
The current convention is to derive, culture and bank hPSCs
from static two dimensional culture systems in a dish or flask1873-5061/$ - see front matter © 2012 Published by Elsevier B.V.
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andrew.laslett@csiro.au (A.L. Laslett).with the use of supporting embryonic fibroblast feeder cells or
semi-defined extracellular matrix components. Apart from
inadequately resembling the in vivo developmental environ-
ment, these systems do not lend themselves to pre-clinical or
future clinical application due to their inherent variability,
time consuming passaging and handling requirements and low
yields. The culture of single hPSCs in a suspension system is
likely the simplest and most robust means by which to gen-
erate cell products suitable for large scale drug and therapy
applications. Since the first report of preformed embryoid
body (EB) culture of hESCs in stirred-suspension bioreactors
(SSBs) in 2004 (Gerecht-Nir et al., 2004) there have been a
number of reports detailing modifications and improvements.
These groups evaluated scalable aggregate, microcarrier and
encapsulation SSB systems in the quest to improve outcomes
for hESC viability, expansion yield, homogeneity, differentia-
tion capacity and applicability to industry processes (reviewed
in Serra et al., 2012; Kehoe et al., 2010; Krawetz et al., 2010).
SSBs that enable the expansion and self-renewal of hPSCs in
clinically compatible conditions and relevant quantities will
require single cell seeding of hPSCs in working volumes upwards
of a few hundred millilitres, the formation of uniform suspen-
sion aggregates and ease of continuous passaging under defined
culture conditions.
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of suspension bioreactors have in the past been hampered by
an increased loss of cell viability and self-renewal. The de-
monstration that exposure of hESCs to the Rho-associated
kinase (ROCK) inhibitor Y-27632 can greatly diminish the
apoptosis associated with single cell dissociation methods and
improve self-renewal (Watanabe et al., 2007, Harb et al., 2008)
has improved outcomes for continual single cell passaging and
maintenance of hPSC cultures using commercially available
enzyme mixes and in both serum and serum-free conditions
(Bajpai et al., 2008).
The ability to culture hPSCs in suspension systems, often
as embryoid bodies, for the purpose of producing differen-
tiated cell types is well documented (Kurosawa, 2007). More
recently, there have been several reports demonstrating some
success with the maintenance, expansion and serial passaging
of undifferentiated hPSCs in stirred and static suspension
culture systems and with the use of ROCK inhibitors (Singh et
al., 2010; Amit et al., 2011; Krawetz et al., 2010; Kehoe et al.,
2010; Olmer et al., 2010, Steiner et al., 2010; Zweigerdt et al.,
2011). These studies have reported very promising outcomes
for the successful expansion and maintenance for a limited
number of passages of hESCs, hiPSCs and a nonhuman primate
ESC line in both static low attachment plates and stirred
suspension cultures in small scale petri dish, Erlenmeyer and
spinner flask formats. hPSC expansion rates in these studies
have been variable however, with respect to initial seeding
densities and overall cell yields were not always comparable to
those achieved with adherent cell cultures (reviewed by Serra
et al., 2012).
Long term maintenance of hPSCs in a scalable
and defined suspension culture system
A report published recently in Stem Cell Research (Chen et
al., 2012, 8:388–402) extends from these previous studies to
demonstrate for the first time, the long term expansion of
hESCs retaining the characteristic traits of pluripotency for
over 20 passages without loss of viability or growth rate in a
scalable GMP compliant spinner flask culture system that is
matrix, serum-free and reagent defined. A calculated cumu-
lative fold expansion over 1×1013 was achieved following 21
passages of the H9 hESC line. Chen et al. demonstrated that at
this passage these cells were still undifferentiated by flow
cytometric analysis of pluripotency markers, and karyotypi-
cally normal.
Chen et al. went on to describe the development of a
stirred spinner flask culture system for the continuous single
cell passaging and aggregate expansion of 3 hESC lines (HES-2,
H1 and H9). This system is equivalent or superior to adherent
culture systems in terms of growth rate, expansion capacity,
viability, maintenance of the pluripotent phenotype and final
yield. Suspension culture conditions were optimized by com-
paring commercially available serum-free defined hPSCmedia
and determining the best seeding density and cell passaging
intervals. In this production system, prior to initiating sus-
pension culture, the hESC cultures are first adapted from
conventional adherent cultures on MEF feeders to feeder-free
adherent culture on a defined xeno-free matrix (CELLstart,
Invitrogen) and in a serum-free defined medium (StemPro hESC
SFM, Invitrogen), andmaintained for more than 3 passages. Thethree cell lines adapted to this defined culture system grew as
monolayer cultures of cells that were shown to express high
levels of the pluripotency markers Tra-1-60, Tra-181, SSEA-4
and Oct-4 by flow cytometry analysis andwere reported to form
teratomas containing lineages representative of the three
embryonic germ layers in immunocompromised mice.
A number of experiments were initially undertaken by
Chen et al. in small scale orbital rotation low attachment
culture wells to determine conditions for transit directly
from the CELLstart adherent hESC cultures to an optimised
defined suspension culture system. Consistent with previous
reports from other groups, the adherent hESC cultures were
demonstrated to form viable cell aggregates following pre-
treatment with the Rho kinase inhibitor Y-27632 and single
cell dissociation using the commercially available enzyme mix
Accutase (Millipore). Similarly, continued exposure to the ROCK
inhibitor appeared to be a key requirement for the further
expansion of aggregates formed in suspension. Aggregates were
typically of 100–120 μm size at day 2 and 150–200 μm at day 3,
retained characteristic pluripotency markers by confocal fluo-
rescence analysis and displayed compact hPSC colony morphol-
ogy and strong alkaline phosphatase staining when replated
back to MEF adherent culture conditions after 4 days in the
defined medium suspension culture. From three media condi-
tions and two seeding densities trialled, the culture of adapted
hESC cells seeded at 2.5×105 cells/ml in StemPro hESC SFM
supplemented with 40 ng/ml human recombinant basic fibro-
blast growth factor (bFGF) and 0.1 mM β-mercaptoethanol and
in the presence of 10 μM Y-27632 was determined as being
optimal for the generation of aggregates with respect to
numbers formed, smaller size and homogeneity (typically
b200 μm), high cell viability, retained expression of markers
for pluripotency by flow cytometry (N90% at day 3) and overall
cell yields. The authors did note some variations in results for
the above parameters for the different cell lines evaluated in
this study. While there is no direct comparison given for the
parent MEF adherent cultures for adaptation to either the small
scale or spinner flask suspension cultures described, the widely
documented variation in both self-renewal and differentiation
outcomes generally seen between different hPSC lines in
culture would suggest variable amenity to this defined culture
adaptation for other hESC and hiPSC cell lines.
As cell aggregates increase in size in culture, so too will
the difficulty for nutrients and cytokines required for the
maintenance of self-renewal to penetrate the 3D cultures,
leading to decreased expansion of hPSCs and increasing dif-
ferentiation. For adapted hESCs seeded in the optimisedmedia
conditions to scaled culture in 125 ml spinner flasks with
magnetic stirrers (Thermo Scientific) set at a pre-determined
70 rpm, Chen et al. demonstrated by flow cytometric analyses a
significant decline in the expression of pluripotency markers
Tra-1-60, Tra-1-81 and Oct-4 after 4 days of suspension culture.
Similarly, growth rates were calculated as starting to decrease
after day 4 although, cell viability remained high at ~90% at day
6 in the same cultures.
Apart from the elimination of feeder and matrices, scal-
ability is the key advantage offered by suspension culture
formats. Adaptation of scalable defined suspension systems to
bioreactor formats where process parameters can be auto-
matically controlled will enable the commercial scale gener-
ation of cGMP compliant cells in the folds that will be a
requirement for pre-clinical and clinical applications. In the
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termmaintenance of pluripotency were demonstrated for the
defined media suspension system scaled to 125 ml or 500 ml
spinner flask cultures with continual single cell passaging
every 3–4 days using Accutase and ROCK inhibitor. Following 9
passages for the three hESC lines and 21 passages (64 days) for
a further study of one line (H9, 64 days), all three hESC lines
consistently displayed a 3–4 fold average expansion per
passage (~1×106 cells/ml each 3–4 days) under these condi-
tions, retained a normal karyotype, and consistently displayed
over 90% expression of pluripotency markers by flow cytom-
etry analyses. hESC cultures had maintained consistently high
viabilities of N90% prior to each passage event in this system,
and an overall expansion of 1.5×1013 fold was calculated
following 21 passages. Compared with MEF adherent cultures
maintained over a 3–4 week period, the suspension cultures
and adherent CELLstart cultures for three hESC lines displayed
higher expansion rates and cell viability. Population doubling
rates were similar for suspension and adherent cultures,
indicating that normal growth characteristics were retained.
All cell lines demonstrated contribution to tissues represen-
tative of the 3 germ layers in teratoma assays at the end of
suspension culture. The H9 line was also examined for in vitro
differentiation capacity in EBs formed from day 3 spinner flask
cultures with the addition of serum. RT-PCR analyses of EBs
plated to matrigel demonstrated undetectable Oct4 and Nanog
expression by day 6 and the onset of T, Sox17, Sox1 and Tubb33
expression during 16 days of adherent culture. The directed
differentiation of H9 suspension cultures in a continuous serum-
free spinner flask EB culture to a cardiomyocyte fate was also
achieved with a reasonable efficiency, as confirmed by flow
cytometry, immunohistochemistry and gene expression analy-
ses for a range of cardiac specific markers. The authors' objec-
tive in this manuscript is to demonstrate a scalable and defined
hPSC maintenance suspension culture system, however, a
valuable extension would be to compare the directed differen-
tiation outcome with parent MEF cultures and in particular to
evaluate the differentiation outcomes for additional hPSC lines
grown to scale in the described suspension culture system. That
the suspension system described by Chen et al. is scalable as
well as compliant with both cGLP and cGMP manufacturing and
cell banking requirements, is an important outcome of this
study. The authors also demonstrated the successful cryopres-
ervation of hESC expanded in this system using a serum-free
defined cyroprotective medium with the inclusion of ROCK
inhibitor, and it is noteworthy that post-thaw cultures demon-
strate at least 85% viability and a high capacity to self-renew
both directly in suspension and conventional adherent culture
conditions. To demonstrate the utility of the described hESC
cell production system as a whole, three hESC lines were ex-
panded from 125 ml to 500 ml scale spinner flasks as previously
described and 200–400 cryovials each with 4×106 cells/vial
were banked under cGLP or cGMP conditions for all cell lines.Conclusions and future directions
The studies reported by Chen et al. demonstrate a cell pro-
duction system for the reagent-defined adaptation and long
term expansion of hPSC suspension cultures in scalable
spinner flasks for over 20 passages, with no loss of viability or
growth rate. The described GMP compliant suspension systemis equivalent or superior to conventional adherent MEF or
matrix systems with respect to maintenance of pluripotency,
growth characteristics, expansion capability and overall yield,
and the hPSCs generated are amenable to cryopreservation in
reagent-defined conditions. As cell densities equivalent to
adherent culture for long term hPSC suspension passaging are
now demonstrated in a spinner flask system, it is reasonable to
propose that this system when introduced to a more sophis-
ticated bioreactor format with controllable processes will be
able to achieve even greater cell yields.
An important application for developments to date for
the expansion of human PSCs in reagent defined and feeder/
matrix-free suspension culture systems will be the transfer of
cell reprogramming technologies from static culture in dishes to
derive, maintain and expand hiPS cells in suspension. Elimina-
tion of TGFβ cytokine signalling from both fetal bovine serum
and feeders will improve the reprogramming environment with
respect to the mesenchymal-to-epithelial transition that is
required for the initiation of reprogramming to pluripotency
(Li et al., 2010). Very recently, two groups independently
demonstrated success with the derivation of iPSCs from
somatic mouse cells in suspension culture conditions without
the supporting feeder or matrix substratum (Fluri et al., 2012
Shafa et al., 2012). Fluri et al. further demonstrated the
directed differentiation of resulting suspension iPSCs in a
continuous suspension culture to contractile cardiac cells. It
will be of much interest going forward to see if a suspension
culture approach can be achieved for the reprogramming of
human cells, which if additional challenges with generating a
clonal hiPSC line can be overcome, would facilitate scale-up of
patient-matched hiPSCs for seeding differentiation assays
geared to clinical trial applications.
At the time of writing, there are new reports describing
improvements to the mechanical strategies and culture envi-
ronment tomaximise the formation, maintenance and yield of
hPSC aggregates while minimising shear stress and loss of
viability (for e.g. Bhatia et al., 2012; Abbasalizadeh et al.,
2012). Other important requirements for translation of basic
research to industry/clinical scale systems are the develop-
ment of robust and sensitive characterisation tools using
genomic, proteomic, metabolomic and/or functional assays
that enable accurate monitoring of cell types in bioreactor
formats. Ultimately, automated cell production systems that
circumvent the need for repeated dissociation and reforma-
tion of aggregates will greatly facilitate future applications.
No doubt there are further developments underway as this
exciting field of work advances towards clinical stem cell
production.References
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